Patent intelligence · US
US 9492378
Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
Patent details — US 9492378
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 15, 2016
- Expiration
- Nov 10, 2036
- Applicant
- Rani Therapeutics, LLC
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/542, A61K2039/545
Quick answer
US 9492378 (Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device) is held by Rani Therapeutics, LLC. Status: granted. Granted Nov 15, 2016. Expires Nov 10, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rani Therapeutics, LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/542, A61K2039/545, A61K38/00, A61K38/1793
More from Rani Therapeutics, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12357555
Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12214019
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12168692
Antibodies targeting CCR2
granted -
US 12128133
Ingestible device with expandable enclosure
granted -
US 12077551
Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases
granted
Related coverage
Frequently asked questions
What is US patent 9492378?
US 9492378 (Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device) is held by Rani Therapeutics, LLC. Status: granted. Granted Nov 15, 2016. Expires Nov 10, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9492378?
Rani Therapeutics, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 148 pharmaceutical patents for this assignee.
When does US 9492378 expire?
Our index shows an expiration date of Nov 10, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.